mAbxience services

In-house, core R&D competencies provide differentiated development capabilities for complex biopharmaceuticals. End-to-end expertise and capabilities across development of the cell line, formulation, upstream and downstream processes, and fill & finish. R&D platform ensures maximum control over quality, efficacy and development of biopharmaceutical medicines adhering to a strict “quality by design” standard. Leveraging cutting edge analytics of the latest innovations in downstream & upstream process development. mAbxience network centers of excellence is in an ongoing expansion with various locations in the European Union and Latin America, and will be consolidated with our brand new 940sqm state-of-the-art biopharma R&D center in León (Spain) which is expected to open in 2022.

Independent CDMO platform with complete range of analytical and development processes to provide clients with end-to-end solutions.

mAbxience is a leading vertically integrated biopharmaceuticals platform. In-house, core R&D competencies provide differentiated development capabilities for complex biosimilars and innovators.

We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial challenged environment. mAbxience currently has 2 biosimilars in different markets worldwide, bevacizumab and rituximab; and is presently working on a very attractive pipeline.